Improving the health of insulin-producing cells in type-2 diabetes
Targeting PFKFB3 kinase for activation of cell competition and elimination of dysfunctional beta-cells in type-2 diabetes
This study is looking at a new way to help people with type-2 diabetes by targeting a specific enzyme to help the body get rid of unhealthy insulin-producing cells and replace them with healthy ones, which could lead to better treatment options for managing the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Metanoia Bio LLC NIH-funded |
| Lab location | 1 site (Beverly Hills, United States) |
| Project ID | NIH-10922398 on NIH RePORTER |
What this research studies
This research investigates a new approach to treat type-2 diabetes by targeting a specific enzyme, PFKFB3, to enhance the body's ability to eliminate dysfunctional insulin-producing beta-cells. The study aims to restore the natural process of cell competition, which helps replace damaged cells with healthy ones. By using a novel mouse model, researchers will explore how activating this enzyme can improve beta-cell function and potentially reverse the progression of diabetes. Patients may benefit from a more effective treatment strategy that focuses on restoring cell health rather than just increasing insulin production.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with type-2 diabetes and have dysfunctional beta-cells.
Not a fit: Patients with type-1 diabetes or those who do not have issues with beta-cell function may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that restore normal function in insulin-producing cells, improving diabetes management.
How similar studies have performed: Previous studies have shown promising results in enhancing cell competition and improving cell function in diabetes, indicating that this approach may be viable.
Where this research is happening
Beverly Hills, United States
- Metanoia Bio LLC — Beverly Hills, United States (Active)
Researchers
- Principal investigator: Greeff, Oppel — Metanoia Bio LLC
- Study coordinator: Greeff, Oppel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.